

Supplemental Digital Content 1. Key inclusion and exclusion criteria for the core and extension studies

Study	Inclusion	Exclusion
population		
Infants and children core studies	<ul style="list-style-type: none"> • Diagnosed SBS • Dependent on PS to provide $\geq 50\%$ (NCT03571516) or $\geq 30\%$ (NCT02980666) of fluid or caloric needs • Stable PS requirements ≥ 1 month prior to screening • Informed consent by the parent or legal guardian • When applicable, informed assent by the patient • Age 4 to <12 months (corrected gestational age, infants) or 1–15 years (children) at screening • Weight ≥ 5 kg at screening and baseline (infants) • Weight-for-length Z-score > -2 at screening (infants) 	<ul style="list-style-type: none"> • Intestinal malabsorption due to a genetic condition • Severe, known dysmotility syndrome that was the primary contributing factor to feeding intolerance and inability to reduce PS, prior to screening • Inability to advance oral or enteral feeding due to lack of access to the gut • Known clinically significant untreated intestinal obstruction contributing to feeding intolerance and inability to reduce PS • Major gastrointestinal surgical intervention in the 3 months prior to screening or planned during the study period • Previous use of teduglutide or native/synthetic GLP-2

		<ul style="list-style-type: none"> • Previous (within 3 months) or concurrent use of GLP-1; GLP-2; insulin-like growth factor-1; growth hormone, somatostatin, or analogs of these hormones; or glutamine • Renal dysfunction (estimated glomerular filtration rate <50 mL/min/1.73 m²)
<p>Infants and children extension study</p>	<ul style="list-style-type: none"> • Completion of study NCT02980666 • Decreased PS requirement during prior teduglutide treatment • Increased PS requirements following teduglutide discontinuation • Deteriorating nutritional status despite maximal tolerated enteral nutrition following teduglutide discontinuation • Deteriorating fluid or electrolyte status despite maximal tolerated enteral fluid and electrolyte intake following teduglutide discontinuation 	<ul style="list-style-type: none"> • As above (excluding prior use of teduglutide)

-
- Cessation of improvements in PS requirements following teduglutide discontinuation

GLP = glucagon-like peptide; PS = parenteral support; SBS = short bowel syndrome.